Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion

International Journal of Hematology

Volumn 91, Issue 5, 2010, Pages 799-807

  Nagata, Yasunobu ^a   Ohashi, Kazuteru ^a   Fukuda, Shiomi ^a   Kamata, Noriko ^a   Akiyama, Hideki ^a   Sakamaki, Hisashi ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Adverse effects; Dasatinib; Large granular lymphocytosis; Philadelphia chromosome; Pleural effusion

Indexed keywords

BCR ABL PROTEIN; DASATINIB; PROTEIN TYROSINE KINASE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD SMEAR; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HUMAN; LARGE GRANULAR LYMPHOCYTE; LYMPHOCYTOSIS; MALE; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; CHEMICALLY INDUCED; COHORT ANALYSIS; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTE; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTES; LYMPHOCYTOSIS; MALE; MIDDLE AGED; PLEURAL EFFUSION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 77954536015     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0565-1     Document Type: Article

References (16)

1. M Talpaz NP Shah H Kantarjian N Donato J Nicoll R Paquette, et al. 2006 Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N Engl J Med 354 2531 2541 10.1056/NEJMoa055229 1:CAS:528:DC%2BD28Xlslyisb0%3D 16775234 (Pubitemid 43882349)
2. A Hochhaus M Baccarani HM Kantarjian JF Apperley JH Lipton SL Goldberg, et al. 2008 Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib Leukemia 22 1200 1206 10.1038/leu.2008.84 1:CAS:528: DC%2BD1cXntVCjurw%3D 18401416 (Pubitemid 351833788)
3. LJ Lombardo FY Lee P Chen D Norris JC Barrish K Behnia, et al. 2004 Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1- yl)-2-methylpyrimidin-4-ylamino)-thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J Med Chem 47 6658 6661 10.1021/jm049486a 1:CAS:528:DC%2BD2cXhtVKrsrnI 15615512 (Pubitemid 40053752)
4. SE McKenzie MP Reilly 2009 The clot thickens (or not) Blood 114 1722 1723 10.1182/blood-2009-06-226720 1:CAS:528:DC%2BD1MXhtFWgsbnP 19713476
5. HJ Khoury F Guilhot TP Hughes DW Kim JE Cortes 2009 Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations Cancer 115 1381 1394 10.1002/cncr.24155 1:CAS:528:DC%2BD1MXksF2ru7g%3D 19195046
6. K Porkka HJ Khoury RL Paquette Y Matloub R Sinha JE Cortes 2010 Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion Cancer 116 377 386 10.1002/cncr.24734 1:CAS:528:DC%2BC3cXitFGit7g%3D 19924787
7. A Bergeron D Réa P Rousselot C Picard V Meignin J Tamburini, et al. 2007 Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series Am J Respir Crit Care Med 176 814 818 10.1164/rccm.200705-715CR 1:CAS:528:DC%2BD2sXhtleru77F 17600277 (Pubitemid 47598483)
8. S Mustjoki M Ekblom TP Arstila I Dybedal PK Epling-Burnette F Guilhot, et al. 2009 Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy Leukemia 23 1398 1405 10.1038/leu.2009.46 1:CAS:528: DC%2BD1MXpvF2kurs%3D 19295545
9. DH Kim S Kamel-Reid JH Lipton R Sutherland CW Jung HJ Kim, et al. 2009 Natural killer or natural killer/T cell lineage large granular lymphocytosis associated dasatinib therapy for Philadelphia chromosome positive leukemia Haematologica 94 135 139 10.3324/haematol.13151 1:CAS:528:DC%2BD1MXis1Wmtrc%3D 19066329
10. M Yamamoto K Kakihana K Ohashi T Yamaguchi K Tadokoro H Akiyama, et al. 2009 Serial monitoring of T315I BCR-ABL mutation by invader assay combined with RT-PCR Int J Hematol 89 482 488 10.1007/s12185-009-0290-9 1:CAS:528: DC%2BD1MXltFWmurg%3D 19343480
11. F Gruber S Mustjoki K Porkka 2009 Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia Br J Haematol 145 581 597 10.1111/j.1365-2141.2009.07666.x 1:CAS:528:DC%2BD1MXmvFyjtbc%3D 19388927
12. SF Wong 2009 Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia J Oncol Pharm Pract 15 17 27 10.1177/ 1078155208094455 1:CAS:528:DC%2BD1MXksFartr4%3D 18753186
13. K Kelly R Swords D Mahalingam S Padmanabhan FJ Giles 2009 Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors Target Oncol 4 99 105 10.1007/s11523-009-0110-4 19381453
14. A Quintás-Cardama H Kantarjian S O'brien G Borthakur J Bruzzi R Munden, et al. 2007 Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure J Clin Oncol 25 3908 3914 10.1200/JCO.2007.12.0329 17761974 (Pubitemid 47477268)
15. H de Lavallade S Punnialingam D Milojkovic M Bua JS Khorashad IH Gabriel, et al. 2008 Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis Br J Haematol 141 745 747 10.1111/j.1365-2141.2008.07108.x 18331365 (Pubitemid 351667633)
16. FJ Giles M O'Dwyer R Swords 2009 Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia Leukemia 23 1698 1707 10.1038/leu.2009.111 1:CAS:528:DC%2BD1MXht1GgtLjK 19474800